Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

View Full Paper
Ask AI
Bookmark
Share

Authors

VLVasiliki LampropoulouINIoannis Ntanasis-StathopoulosMGMaria Gavriatopoulou

Discussion

Loading...

Member takes

Overview

Final analysis demonstrates improved hematologic response and safety profile for isatuximab in multiple myeloma patients with severe renal impairment.

Key Points

  • Progression-free survival was 77.6% at 12 months and 60.3% at 24 months.
  • Among 51 patients, 36 achieved a major renal response, indicating significant renal function recovery after treatment.
  • Assessment involved six cycles of induction therapy with isatuximab, bortezomib, cyclophosphamide, and dexamethasone followed by maintenance with lenalidomide.
  • Findings support isatuximab combination therapy as a promising frontline treatment for multiple myeloma in those with severe renal impairment.

Cite This Study

Lampropoulou et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da87https://doi.org/10.1182/blood-2025-4036
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)2025
  2. 2Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)2025 · 1 citations
  3. 3Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)2025
  4. 4An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.2025 · 1 citations
  5. 5Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients2025 · 1 citations